For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
1
views
45
references
 Top references
cited by
6
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      92
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Quality indicators and excellence requirements for a multidisciplinary lung cancer tumor board by the Spanish Lung Cancer Group

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Multidisciplinary care is needed to decide the best therapeutic approach and to provide optimal care to patients with lung cancer (LC). Multidisciplinary teams (MDTs) are optimal strategies for the management of patients with LC and have been associated with better outcomes, such as an increase in quality of life and survival. The Spanish Lung Cancer Group has promoted this review about the current situation of the existing national LC-MDTs, which also offers a set of excellence requirements and quality indicators to achieve the best care in any patient with LC. Time and sufficient resources; leadership; administrative and institutional support; and recording of activity are key factors for the success of LC-MDTs. A set of excellence requirements in terms of staff, resources and organization of the LC-MDT have been proposed. At last, a list of quality indicators has been agreed to achieve and measure the performance of current LC-MDTs.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Early palliative care for patients with metastatic non-small-cell lung cancer.

          Jennifer Temel, Joseph A. Greer, Alona Muzikansky … (2010)
          Patients with metastatic non-small-cell lung cancer have a substantial symptom burden and may receive aggressive care at the end of life. We examined the effect of introducing palliative care early after diagnosis on patient-reported outcomes and end-of-life care among ambulatory patients with newly diagnosed disease. We randomly assigned patients with newly diagnosed metastatic non-small-cell lung cancer to receive either early palliative care integrated with standard oncologic care or standard oncologic care alone. Quality of life and mood were assessed at baseline and at 12 weeks with the use of the Functional Assessment of Cancer Therapy-Lung (FACT-L) scale and the Hospital Anxiety and Depression Scale, respectively. The primary outcome was the change in the quality of life at 12 weeks. Data on end-of-life care were collected from electronic medical records. Of the 151 patients who underwent randomization, 27 died by 12 weeks and 107 (86% of the remaining patients) completed assessments. Patients assigned to early palliative care had a better quality of life than did patients assigned to standard care (mean score on the FACT-L scale [in which scores range from 0 to 136, with higher scores indicating better quality of life], 98.0 vs. 91.5; P=0.03). In addition, fewer patients in the palliative care group than in the standard care group had depressive symptoms (16% vs. 38%, P=0.01). Despite the fact that fewer patients in the early palliative care group than in the standard care group received aggressive end-of-life care (33% vs. 54%, P=0.05), median survival was longer among patients receiving early palliative care (11.6 months vs. 8.9 months, P=0.02). Among patients with metastatic non-small-cell lung cancer, early palliative care led to significant improvements in both quality of life and mood. As compared with patients receiving standard care, patients receiving early palliative care had less aggressive care at the end of life but longer survival. (Funded by an American Society of Clinical Oncology Career Development Award and philanthropic gifts; ClinicalTrials.gov number, NCT01038271.)
          Article 0 comments Cited 669 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

            D Planchard, S Popat, K Kerr … (2018)
            Article 0 comments Cited 603 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The Effect of Advances in Lung-Cancer Treatment on Population Mortality

              Nadia Howlader, Gonçalo Forjaz, Meghan Mooradian … (2020)
              Article 0 comments Cited 511 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                C. Teixido:
                ORCID: http://orcid.org/0000-0002-7226-6567
                teixido@clinic.cat
                Journal
                Journal ID (nlm-ta): Clin Transl Oncol
                Journal ID (iso-abbrev): Clin Transl Oncol
                Title: Clinical & Translational Oncology
                Publisher: Springer International Publishing (Cham )
                ISSN (Print): 1699-048X
                ISSN (Electronic): 1699-3055
                Publication date (Electronic): 19 October 2021
                Publication date PMC-release: 19 October 2021
                Pages: 1-14
                Affiliations
                [1 ]GRID grid.411093.e, ISNI 0000 0004 0399 7977, Medical Oncology Department, , Hospital General Universitario de Elche, ; 03203 Elche, Spain
                [2 ]GRID grid.452472.2, ISNI 0000 0004 1770 9948, Medical Oncology Department, , Consorcio Hospitalario Provincial de Castellón, ; 12002 Castellón de la Plana, Spain
                [3 ]GRID grid.411129.e, ISNI 0000 0000 8836 0780, Pathology Department, , Bellvitge University Hospital, ; 08907 L’Hospitalet de Llobregat, Spain
                [4 ]Thoracic Oncology Unit, Department of Pathology, IDIBAPS, Hospital Clinic of Barcelona, C. de Villarroel, 170, 08036 Barcelona, Spain
                [5 ]GRID grid.411048.8, ISNI 0000 0000 8816 6945, Department of Radiation Oncology, , Hospital Clínico Universitario Santiago de Compostela, ; 15706 Santiago de Compostela, Spain
                [6 ]GRID grid.411057.6, ISNI 0000 0000 9274 367X, Thoracic Surgery Department, , Hospital Clínico Universitario Valladolid, ; 47005 Valladolid, Spain
                Author information
                http://orcid.org/0000-0002-7226-6567
                Article
                Publisher ID: 2712
                DOI: 10.1007/s12094-021-02712-8
                PMC ID: 8525055
                PubMed ID: 34665437
                SO-VID: 0a9f5c6f-9f7f-4f4e-b70d-f06c4e9425e8
                Copyright © © The Author(s) 2021
                License:

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                Date received : 3 August 2021
                Date accepted : 18 September 2021
                Funding
                Funded by: novartis oncology
                Categories
                Subject: Review Article

                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: lung neoplasms (mesh),quality indicators (mesh),quality of health care (mesh),multidisciplinary team,tumor board
                Data availability:
                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: lung neoplasms (mesh), quality indicators (mesh), quality of health care (mesh), multidisciplinary team, tumor board

                Comments

                Comment on this article

                scite_

                Similar content92

                See all similar

                Cited by6

                See all cited by

                Most referenced authors618

                See all reference authors